Bright Minds Biosciences (DRUG) Price & Analysis

Compare

238 Followers

DRUG Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.94 - $79.02

Previous Close$40.4

Volume34.65K

Average Volume (3M)54.51K

Market Cap

C$239.64M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta4.49

Next Earnings

Sep 01, 2025

EPS Estimate

-0.58

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.31

Shares Outstanding7,083,239

10 Day Avg. Volume42,641

30 Day Avg. Volume54,505

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$82.50

Price Target Upside136.93% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Financial StabilityBright Minds Biosciences has an adequate cash position to support operations for the next 12 months, indicating financial stability.

Market OpportunityThere is a $1.1B in peak potential in absence alone, if BMB-101 is successfully developed.

Therapeutic PotentialThe unique Gq-biased 5-HT2C mechanism and robust preclinical and Phase 1 dataset of BMB-101 distinguish it from peers, supporting a best-in-class therapeutic profile.

Bears Say

Clinical RiskThe clinical risk remains very high given the limited data available.

Financial RiskThe company only has approximately $30M of cash on hand, thus it will need to raise money in the near-term which may significantly dilute current shareholders.

Bright Minds Biosciences News

Psychedelic: atai Life Sciences, Beckley Psytech report BPL-003 study results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

27d ago

ATAI

CMND

Bright Minds assumed with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage of Bright Minds (DRUG) with an Overweight rating and no price target Bright Minds’...

29d ago

DRUG

Bright Minds Biosciences to Present at 2025 Jefferies Global Healthcare Conference

Bright Minds Biosciences ( ($TSE:DRUG) ) has provided an announcement. Bright Minds Biosciences announced that its CEO and...

2M ago

DRUG

Bright Minds Biosciences’ BMB-101: A Promising Breakthrough in Treatment-Resistant Epilepsy

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Bright Minds Biosciences...

2M ago

DRUG

Bright Minds Biosciences: Buy Rating Issued on Promising Potential of BMB-101 for Absence Seizures

TD Cowen analyst Joseph Thome has maintained their bullish stance on DRUG stock, giving a Buy rating on...

2M ago

DRUG

Bright Minds Biosciences Hosts Virtual R&D Day on Absence Epilepsy

Bright Minds Biosciences ( ($TSE:DRUG) ) has provided an update. Bright Minds Biosciences announced the featured speakers for...

2M ago

DRUG

Bright Minds announces speakers for Absence epilepsy R&D Day

Bright Minds (DRUG) Biosciences announced the featured speakers for its virtual R&D Day on Tuesday, May 20, 2025,...

2M ago

DRUG

VA secretary wants to find answers on psychedelics therapies, Politico says

Veterans Affairs Secretary Doug Collins wants to find out whether psychedelic drugs can successfully treat veterans with PTSD...

3M ago

ATAI

CYBN

Psychedelic: Atai, Enveric, Incannex and Relmada report quarterly results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

3M ago

TMO

ATAI

Bright Minds Biosciences Reports Promising Results for Epilepsy Treatment

An update from Bright Minds Biosciences ( ($TSE:DRUG) ) is now available. Bright Minds Biosciences announced positive results...

3M ago

DRUG

Coinbase, Caterpillar upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

3M ago

BRO

CAT

Bright Minds announces findings from mouse model study of BMB-101

Bright Minds (DRUG) Biosciences announced findings from its DBA/2 mouse model study. BMB-101, the Company’s novel scaffold 5-HT2C...

3M ago

DRUG

Bright Minds initiated with a Buy at TD Cowen

TD Cowen analyst Joseph Thome initiated coverage of Bright Minds (DRUG) with a Buy rating and no price...

3M ago

DRUG

Bright Minds Biosciences’ BMB-101: A Promising Anti-Seizure Drug with Billion-Dollar Market Potential

Joseph Thome, an analyst from TD Cowen, has initiated a new Buy rating on Bright Minds Biosciences (DRUG)....

3M ago

DRUG

DRUG FAQ

What was Bright Minds Biosciences’s price range in the past 12 months?

Bright Minds Biosciences lowest stock price was $0.94 and its highest was $79.02 in the past 12 months.

What is Bright Minds Biosciences’s market cap?

Bright Minds Biosciences’s market cap is C$239.64M.

When is Bright Minds Biosciences’s upcoming earnings report date?

Bright Minds Biosciences’s upcoming earnings report date is Sep 01, 2025 which is in 32 days.

How were Bright Minds Biosciences’s earnings last quarter?

Bright Minds Biosciences released its earnings results on May 15, 2025. The company reported -$0.305 earnings per share for the quarter, beating the consensus estimate of -$0.315 by $0.01.

Is Bright Minds Biosciences overvalued?

According to Wall Street analysts Bright Minds Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bright Minds Biosciences pay dividends?

Bright Minds Biosciences does not currently pay dividends.

What is Bright Minds Biosciences’s EPS estimate?

Bright Minds Biosciences’s EPS estimate is -0.58.

How many shares outstanding does Bright Minds Biosciences have?

Bright Minds Biosciences has 7,083,239 shares outstanding.

What happened to Bright Minds Biosciences’s price movement after its last earnings report?

Bright Minds Biosciences reported an EPS of -$0.305 in its last earnings report, beating expectations of -$0.315. Following the earnings report the stock price went up 1.978%.

Which hedge fund is a major shareholder of Bright Minds Biosciences?

Currently, no hedge funds are holding shares in DRUG

Bright Minds Biosciences Stock Smart Score

Underperform

Fundamentals

Return on Equity

-11.21%

Trailing 12-Months

Asset Growth

764.61%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bright Minds Biosciences

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

Bright Minds Biosciences (DRUG) Earnings & Revenues

DRUG Earnings Data >

DRUG Stock 12 Month Forecast

Average Price Target

$82.50

▲(136.93%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","85":"$85","21.25":"$21.3","42.5":"$42.5","63.75":"$63.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":84.9999999269085,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$85.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":82.49940948,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$82.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":79.999999931208,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$80.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,21.25,42.5,63.75,85],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Nov<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.58,31.07384614822373,35.56769229644746,40.061538444671186,44.555384592894924,49.04923074111865,53.54307688934238,58.03692303756611,62.53076918578984,67.02461533401357,71.51846148223731,76.01230763046104,80.50615377868476,{"y":84.9999999269085,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.58,30.881493036923075,35.18298607384615,39.48447911076923,43.785972147692306,48.08746518461538,52.38895822153846,56.690451258461536,60.99194429538461,65.29343733230769,69.59493036923077,73.89642340615384,78.19791644307692,{"y":82.49940948,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.58,30.689230763939076,34.79846152787815,38.90769229181723,43.01692305575631,47.12615381969538,51.235384583634456,55.34461534757354,59.45384611151261,63.563076875451685,67.67230763939077,71.78153840332985,75.89076916726891,{"y":79.999999931208,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.21,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.05,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.15,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.06,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.1,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":48.18,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":48.18,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.02,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.11,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.32,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.58,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >